ReviewCureus2026
Effect of Sodium Restriction on Cardiovascular Outcomes in Patients With Hypertension and Heart Failure: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dietary sodium restriction is a cornerstone of cardiovascular disease management guideline recommendations. However, sodium restriction's impact on hard clinical endpoints in patients with heart failure remains controversial, showing conflicting results compared to the established benefits in essential hypertension. A systematic review and meta-analysis of randomized controlled trials (RCTs) and observational cohort studies evaluating the effect of sodium restriction on all-cause mortality and cardiovascular hospitalization was conducted. Databases were searched through December 2025. Random-effects models were used to pool hazard ratios (HR) with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic, and potential bias was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool and Newcastle-Ottawa Scale. A total of 20 studies (11 RCTs, nine observational cohorts) involving 306,019 participants were included. In RCTs, the impact of sodium restriction varied significantly by clinical population. While restriction reduced mortality risk in patients with hypertension, it showed a non-significant trend toward harm in patients with established heart failure. In observational studies, low sodium intake was associated with increased mortality risk, supporting a J-shaped relationship. These findings suggest that while sodium restriction is beneficial for hypertension, aggressive restriction in heart failure may not improve outcomes and could be detrimental. This challenges uniform guideline recommendations and highlights the urgent need for personalized dietary management. In observational studies, low sodium intake was associated with increased mortality risk (HR, 1.20 (1.05-1.38)), supporting a J-shaped relationship. Sodium restriction is beneficial for mortality reduction in hypertension but does not improve clinical outcomes in heart failure patients and may be associated with harm in restrictive (<1.5 g/day) regimens. These findings challenge current uniform guideline recommendations for aggressive sodium restriction in heart failure and suggest a need for personalized dietary management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.